Table 1.
Cell culturing conditions.
| Name | Short name | Cell type and origin | Supplier | Cell culture medium | Cell culture drug supplement |
|---|---|---|---|---|---|
| HCC827 parental | HCC827 | Human NSCLC epithelial cell line | #CRL-2868, ATCC (HCC827) | RPMI1640 (R8758, Sigma)* | NA |
| HCC827 ER3, | ER3, | Erlotinib-resistant clones of HCC827 | #CRL-2868, ATCC (HCC827) 1,2 | RPMI1640 (R8758, Sigma)* | 1µM erlotinib |
| HCC827 ER10, | ER10, | ||||
| HCC827 ER20, | ER20, | ||||
| HCC827 ER30 | ER30 | ||||
| H1975 parental | H1975 | Human NSCLC (adenocarcinoma) epithelial cell line | #CRL-5908, ATCC (H1975) | RPMI1640 (R8758, Sigma)* | NA |
| H1975 COR1-1, H1975 COR10-1 | COR1-1, | Rociletinib-resistant clones of H1975 | #CRL-5908, ATCC (H1975) 3 | RPMI1640 (R8758, Sigma)* | 1µM rociletinib |
| COR10-1 | |||||
| SV80 | SV80 | Human lung fibroblast (SV40-transformed cell line) | CLS Cell Lines Service GmbH | DMEM/F12 (D8062, Sigma)* | NA |
| MRC-5 | MRC-5 | Human lung fibroblasts | #CCL-171, ATCC | DMEM (D5671, Sigma)* | NA |
1ER3 clone provided by Professor Trever G. Bivona at the Division of Hematology/Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Fransisco, CA, USA (Zhang et al., 2012).
2ER10, ER20, and ER30 clones were developed at the Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
3Rociletinib-resistant clones provided by Clovis oncology.
*All cell culture media were also supplemented with 5% heat-inactivated FBS (Gibco), 20 Units/ml Penicillin, 20 ug/ml Streptomycin (Penicillin-Streptomycin, #P-0781, Sigma) and 2 mM L-glutamine (#G-0781, Sigma).
NA, not applicable.